Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Nov;23(6):377-82.
doi: 10.1007/s12264-007-0056-4.

How to improve the survival of the fetal ventral mesencephalic cell transplanted in Parkinson's disease?

Jia Liu  1 , Hong-Yun Huang
Affiliations
Review

How to improve the survival of the fetal ventral mesencephalic cell transplanted in Parkinson's disease?

Jia Liu et al. Neurosci Bull. 2007 Nov.

Abstract
in English, Chinese

It has been extensively confirmed that fetal ventral mesencephalic cell (VMC) transplantation can ameliorate the symptoms of Parkinson's disease (PD). But there are still several problems to be resolved before the extensive clinical application of this technology. The major limitations are the poor survival of grafted dopamine (DA) neurons and restricted dopaminergic reinnervation of host striatum. Some attempts have been made to solve these problems including use of some trophic factor and co-transplantation with neural/paraneural origins. The purpose of this review is to overview advances of the means improving the survival of grafts and their current limitations.

虽然胚胎中脑细胞移植对帕金森病的疗效已得到广泛证实, 但在这项技术广泛应用于临床之前仍有一些问题亟待解决。 其中主要是移植物存活率低和宿主纹状体神经支配恢复有限。 迄今为止, 人们尝试了很多方法来解决这些问题, 包括神经营养因子的广泛应用, 以及神经和(或)非神经来源组织的联合移植。 本文将对目前 的胚胎中脑细胞移植术中所用的神经保护手段及其局限性进行简要的介绍。

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lindvall O., Bjorklund A. Cell Therapy in Parkinson’s Disease. NeuroRx. 2004;1:382–393. doi: 10.1602/neurorx.1.4.382. - DOI - PMC - PubMed
    1. Goren B., Kahveci N., Eyigor O., Alkan T., Korfali E., Ozluk K. Effects of intranigral vs intrastriatal fetal mesencephalic neural grafts on motor behavior disorders in a rat Parkinson model. Surg Neurol. 2005;64(Suppl2):S33–S41. doi: 10.1016/j.surneu.2005.07.038. - DOI - PubMed
    1. Collier T.J., Sortwell C.E., Elsworth J.D., Taylor J.R., Roth R.H., Sladek J.R., Jr, et al. Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: feasibility relevant to multiple-target grafting as a therapy for Parkinson’s disease. J Comp Neurol. 2002;442:320–330. doi: 10.1002/cne.10108. - DOI - PubMed
    1. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol. 2003;54:403–414. doi: 10.1002/ana.10720. - DOI - PubMed
    1. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med. 2001;344:710–719. doi: 10.1056/NEJM200103083441002. - DOI - PubMed